

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 44

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 44

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.


On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)


Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 44

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

<i>Proposed INN (Latin, English, French, Spanish)</i>	<i>Chemical name or description: Action and use: Molecular formula Chemical Abstracts Service (CAS) registry number: Graphic formula</i>
<i>DCI Proposée</i>	<i>Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée</i>
<i>DCI Propuesta</i>	<i>Nombre químico o descripción: Acción y uso: Fórmula empírica Número de registro del CAS: Fórmula desarrollada</i>
adalimumabum adalimumab	immunoglobulin G 1 (human monoclonal D2E7 heavy chain anti-human tumor necrosis factor), disulfide with human monoclonal D2E7k-chain, dimer
adalimumab	immunoglobuline G1, anti-(facteur a de nécrose tumorale humain) (chaîne lourde de l'anticorps monoclonal humain D2E7), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain D2E7
adalimumab	inmunoglobulina G1 (anti-factor α de necrosis tumoral humano), dímero del disulfuro de la cadena pesada D2E7 monoclonal humana con la cadena κ D2E7 monoclonal humana
adrogolidum adrogolide	(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propylbenzo[<i>f</i>]thieno[2,3- <i>c</i>]quinoline-9,10-diol diacetate (ester)
adrogolide	diacétate de (5aR,11bS)-2-propyl-4,5,5a,6,7,11b-hexahydrobenzo[<i>f</i>]thieno-[2,3- <i>c</i>]quinoléine-9,10-diyle
adrogolida	diacetato (éster)de (5aR,11bS)-4,5,5a,6,7,11b-hexahidro-2-propilbenzo=[<i>f</i>]tieno[2,3- <i>c</i>]quinolina-9,10-dilo C ₂₂ H ₂₅ NO ₄ S
	
alemcialum alemcial	8,9-didehydro- <i>N</i> -demethyl-9-deoxo-4''',6,12-trideoxy-6,9-epoxy- <i>N</i> -ethylerythromycin
alemcial	(2 <i>R</i> ,3 <i>S</i> ,4 <i>R</i> ,5 <i>R</i> ,8 <i>R</i> ,9 <i>S</i> ,10 <i>S</i> ,11 <i>R</i> ,12 <i>R</i>)-5-éthyl-11-[[3-(éthylméthylamino)-3,4,6-tridésoxy-β-D-xylo-hexopyranosyl]oxy]-3-hydroxy-2,4,8,10,12,14-hexaméthyl-9-[(3- <i>C</i> -méthyl-3- <i>O</i> -méthyl-2,4,6-tridésoxy-α-L-erythro-hexopyranosyl)oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-én-7-one

alemical

8,9-dideshidro-*N*-desmetil-9-desoxo-4",6,12-tridesoxi-6,9-epoxi-*N*-etileritromicinaC₃₈H₆₇NO₁₀**altiniclinum**

altinicline


(-)-5-ethynilnicotine

altinicline

(-)-3-éthynyl-5-[(2*S*)-1-méthylpyrrolidin-2-yl]pyridine

altiniclina

(-)-5-etinilnicotina

C₁₂H₁₄N₂**amiglumidum**


amiglumide

(R)-4-(2-naphthamido)-*N,N*-dipentylglutaramic acid

amiglumide

acide (4*R*)-5-(dipentylamino)-4-[(naphthalén-2-ylcarbonyl)amino]-5-oxopentanoïque

amiglumida

(R)-4-(2-naftamido)-*N,N*-dipentilglutarámicoC₂₆H₃₆N₂O₄

anispermusum


anispermus

[(6-guanidinohexyl)carbamoyl]methyl [4-[[*(R)*-3-aminobutyl]amino]butyl]=
carbamate

anispermus

[4-[[*(3R)*-3-aminobutyl]amino]butyl]carbamate de
2-[(6-guanidinohexyl)amino]-2-oxoéthyle

anispermus

[4-[[*(R)*-3-aminobutyl]amino]butyl]carbamato de
[(6-guanidinohexil)carbamoil]metilo $C_{18}H_{39}N_7O_3$ **ataquimastum**


ataquimast

1-ethyl-3-(methylamino)-2(1*H*)-quinoxalinone

ataquimast

1-éthyl-3-(méthylamino)quinoxalin-2(1*H*)-one

ataquimast

1-etil-3-(metilamino)-2(1*H*)-quinoxalinona $C_{11}H_{13}N_3O$ **axitiromum**


axitirome

ethyl (±)-4'-[[α-(*p*-fluorophenyl)-α,4-dihydroxy-*m*-tolyl]oxy]-
3',5'-dimethyloxanilate

axitirome

[[4-[3-[[*(RS)*-(4-fluorophényl)hydroxyméthyl]-4-hydroxyphénoxy]-
3,5-diméthylphényl]amino]oxoacétate d'éthyle

axitiromo

(±)-4'-[[α-(*p*-fluorofenil)-α,4-dihidroxil-*m*-tolil]oxil]-3',5'-dimetiloxanilato de etilo $C_{25}H_{24}FNO_6$ and enantiomer
et énantiomère
y enantiómero

bilastinum


bilastine

p-[2-[4-[1-(2-ethoxyethyl)-2-benzimidazolyl]piperidino]ethyl]- α -methylhydratropic acid

bilastine

acide 2-[4-[2-[4-[1-(2-éthoxyéthyl)-1*H*-benzimidazol-2-yl]pipéridin-1-yl]éthyl]phényl]-2-méthylpropanoïque

bilastina

ácido *p*-[2-[4-[1-(2-etoxietil)-2-bencimidazolil]piperidino]etil]- α -metilhidratrópico $C_{28}H_{37}N_3O_3$ **binetrakinum**

binetrakin

interleukin 4 (human)

binétrakine

interleukine 4 humaine

binetrakina

interleuquina 4 (humana)

HKCDITLQEI	IKTLNSLTEQ	KTLCTELTVT	DIFAASKNTT
EKETFCRAAT	VLRQFYSHHE	KDTRCLGATA	QQFHRHKQLI
RFLKRDRNL	WGLAGLNSCP	VKEANQSTLE	NFLERLKTIM
REKYSKCSS			

cangrelorum

cangrelor

N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene)diphosphonic acid

cangrélor

monoanhydride dichlorométhylènediphosphonique *N*-[2-(méthylsulfanyl)éthyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]-5'-adénylique

cangrelor

monoanhidrido del ácido *N*-[2-(metiltio)etil]-2-[(3,3,3-trifluoropropil)tio]-5'-adenílico con ácido (diclorometileno)difosfónico

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.